Skip to main content
. 2018 Aug 1;7:F1000 Faculty Rev-1170. [Version 1] doi: 10.12688/f1000research.14874.1

Table 1. Selected promising antimalarial compounds.

Antimalarial
compound		 Alternative
names		 Protein target/predicted
target		 Target candidate profiles a Current status in MMV pipeline b
Artefenomel OZ439 Unknown Asexual parasite clearance;
transmission blocking		 Combined artefenomel–ferroquine is
in the patient-exploratory stage
Cipargamin KAE609,
NITD609		 PfATP4, based on resistance
screen mutations 23 		Asexual parasite clearance;
transmission blocking		 Patient-exploratory stage
DSM265 Not applicable Plasmodium DHODH 24 Asexual parasite clearance;
targeting liver schizonts		 Patient-exploratory stage
Ferroquine SSR97193 Unknown Asexual parasite clearance;
transmission blocking		 Combined artefenomel–ferroquine is
in the patient-exploratory stage
KAF156 GNF156 PfCARL 25, PfACT, and PfUGT 26,
based on resistance screen
mutations		 Asexual parasite clearance;
transmission blocking;
targeting liver schizonts		 Combined KAF156–lumefantrine is in
the patient-exploratory stage
MMV048 MMV390048 Plasmodium PI4K 27 Asexual parasite clearance;
transmission blocking;
targeting liver schizonts		 Patient-exploratory stage
SJ733 (+)-SJ000557733 PfATP4, based on resistance
screen mutations 28, 29 		Asexual parasite clearance;
transmission blocking		 Human volunteer stage
Tafenoquine WR 238605,
Etaquine		 Unknown Targeting Plasmodium
hypnozoites		 Regulatory review stage

DHODH, dihydroorotate dehydrogenase

PI4K, phosphatidylinositol 4-kinase

aAccording to Medicines for Malaria Venture (MMV) Target Candidate Profile classification.

bStatus as of 31 July 2018.